Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: Is it dependent on oestrogen deficiency?

Breast Cancer Research and Treatment

Volumn 123, Issue 3, 2010, Pages 805-814

  Cameron, David A ^a,b   Douglas, Sharon ^a,b   Brown, Janet E ^b   Anderson, Richard A ^c  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Adjuvant chemotherapy; Bone health; Bone mineral density; Bone turnover biomarkers; Breast cancer

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANASTROZOLE; CARBOXY TERMINAL TELOPEPTIDE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; METHOTREXATE; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; ESTRADIOL;

ADULT; AGE DISTRIBUTION; AMENORRHEA; ARTICLE; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY CANCER; ESTRADIOL BLOOD LEVEL; ESTROGEN DEFICIENCY; FEMALE; HIP; HUMAN; LUMBAR SPINE; MENSTRUAL CYCLE; OVARY FUNCTION; PREMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF REPORT; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; BLOOD; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; LUMBAR VERTEBRA; METABOLISM; OSTEOPOROSIS; OVARY; PATHOPHYSIOLOGY; PELVIC GIRDLE; PHOTON ABSORPTIOMETRY; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

ABSORPTIOMETRY, PHOTON; AMENORRHEA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BONE DENSITY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTRADIOL; FEMALE; HUMANS; LUMBAR VERTEBRAE; MENSTRUAL CYCLE; OSTEOPOROSIS; OVARY; PELVIC BONES; PREMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCOTLAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952118143     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0899-7     Document Type: Article

References (29)

1. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347 (Pubitemid 27167365)
2. Vehmanen L, Saarto T, Elomaa I, Makela P, Valimaki M, Blomqvist C (2001) Long-Term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 37:2373-2378 (Pubitemid 33097473)
3. Powles TJ, Hickish T, Kanis J (1996) Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84 (Pubitemid 26022463)
4. Vehmanen L, Elomaa I, Blomqvist C, Saarto T (2006) Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 24:675-680 (Pubitemid 46630433)
5. Petrek JA, Naughton MJ, Case LD et al (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol 24:1045-1051 (Pubitemid 46638800)
6. Shapiro CL, Phillips G, van Poznak CH et al (2005) Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. Breast Cancer Res Treat 90:41-46 (Pubitemid 40487000)
7. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA (2006) The effects of chemotherapy and long-Term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21:2583-2592 (Pubitemid 44542149)
8. Tothill P, Hannan WJ (2007) Precision and accuracy of measuring changes in bone mineral density by dual-energy X-ray absorptiometry. Osteoporos Int 18:1515-1523 (Pubitemid 47512673)
9. Hines SL, Mincey BA, Sloan JA et al (2009) Phase III randomised, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 27:1047-1053
10. Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. [see comments]. J Clin Oncol 19:3306-3311 (Pubitemid 32642182)
11. Hershman DM, McMahon DJ, Crew KD et al (2008) Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 26:4739-4745
12. Rosenbrock H, Seifert-Klauss V, Kaspar S et al (2002) Changes of biochemical bone markers during the menopausal transition. Clin Chem Lab Med 40:143-151 (Pubitemid 34257828)
13. Hadji P, Ziller M, Maskow C et al (2009) The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. Eur J Cancer 45:3205-3212
14. Peris P, Alvarez L, Monegal A et al (2002) Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy. J Bone Miner Metab 20:116-120 (Pubitemid 34205209)
15. Peris P, Alvarez L, Monegal A et al (1999) Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. Bone 25:349-353 (Pubitemid 29406061)
16. Zekri JM, Brown JE, Gutcher S, Ellis S, Coleman R (2007) Effects of high dose chemotherapy and autologous peripheral stem cells transplantation on skeletal health. Clinical Oncology (Royal College of Radiologists) 16, S27, Abstract P2.01
17. Sun L, Peng Y, Sharrow AC et al (2006) FSH directly regulates bone mass [see comment]. Cell 125:247-260
18. Seibel MJ, Dunstan CR, Zhou H, Allan CM, Handelsman DJ (2006) Sex steroids, not FSH, influence bone mass. Cell 127:1079 (Pubitemid 44894538)
19. Banfi A, Podesta M, Fazzuoli L et al (2001) High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: A mechanism for post-bone marrow transplantation osteopenia. Cancer 92:2419-2428 (Pubitemid 33029088)
20. Van Leeuwen BL, Verkerke GJ, Hartel RM et al (2003) Chemotherapy decreases epiphyseal strength and increases bone fracture risk. Clin Orthop Relat Res 4:243-254 (Pubitemid 38063318)
21. Van Leeuwen BL, Kamps WA, Jansen HW, Hoekstra HJ (2000) The effect of chemotherapy on the growing skeleton. Cancer Treat Rev 26:363-376
22. Bjarnason NH, Hitz M, Jorgensen NR (2008) Adverse bone effects during pharmacological breast cancer therapy. Acta Oncol 47:747-754 (Pubitemid 351878449)
23. Wheeler DL, Vander Griend RA, Wronski TJ, Miller GJ, Keith EE, Graves JE (1995) The short-And long-Term effects of methotrexate on the rat skeleton. Bone 16:215-221
24. Gram J, Junker P, Nielsen HK, Bollerslev J (1998) Effects of short-Term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men. Bone 23:297-302 (Pubitemid 28434675)
25. Geusens P, Vanderschueren D, Verstraeten A et al (1991) Shortterm course of 1, 25(OH)2D3 stimulates osteoblasts but not osteoclasts in osteoporosis and osteoarthritis. Calcif Tissue Int 49:168-173
26. Prummel MF, Wiersinga WM, Lips P et al (1991) The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrin Metab 72:382-386 (Pubitemid 21921703)
27. Fuleihan GE-J, Salamoun M, Mourad YA et al (2005) Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: A randomized controlled trial. J Clin Endocrinol Metab 90:3209-3214 (Pubitemid 41014277)
28. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25: 820-828 (Pubitemid 350002882)
29. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822 (Pubitemid 46698462)